MA33299B1 - Nouvelle formulation de naproxène - Google Patents

Nouvelle formulation de naproxène

Info

Publication number
MA33299B1
MA33299B1 MA34386A MA34386A MA33299B1 MA 33299 B1 MA33299 B1 MA 33299B1 MA 34386 A MA34386 A MA 34386A MA 34386 A MA34386 A MA 34386A MA 33299 B1 MA33299 B1 MA 33299B1
Authority
MA
Morocco
Prior art keywords
naproxen
new
compositions
naproxen formulation
methods
Prior art date
Application number
MA34386A
Other languages
Arabic (ar)
English (en)
Inventor
Felix Meiser
Marck Norret
Adrian Russell
H William Bosch
Aaron Dodd
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901746A external-priority patent/AU2009901746A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MA33299B1 publication Critical patent/MA33299B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés de production de particules de naproxène au moyen de processus de broyage à sec ainsi que des compositions comprenant du naproxène, des médicaments produits à l'aide de naproxène sous forme particulaire et/ou des compositions, et concerne également des méthodes de traitement d'un animal, y compris l'homme, au moyen d'une quantité thérapeutiquement efficace de naproxène administré à l'aide desdits médicaments.
MA34386A 2009-04-24 2010-04-23 Nouvelle formulation de naproxène MA33299B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17228909P 2009-04-24 2009-04-24
AU2009901746A AU2009901746A0 (en) 2009-04-24 A Novel Formulation of Naproxen
PCT/AU2010/000470 WO2010121326A1 (fr) 2009-04-24 2010-04-23 Nouvelle formulation de naproxène

Publications (1)

Publication Number Publication Date
MA33299B1 true MA33299B1 (fr) 2012-05-02

Family

ID=43010609

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34386A MA33299B1 (fr) 2009-04-24 2010-04-23 Nouvelle formulation de naproxène

Country Status (19)

Country Link
US (5) US20120148634A1 (fr)
EP (1) EP2421512A4 (fr)
JP (2) JP6116244B2 (fr)
KR (3) KR20160135370A (fr)
CN (2) CN102438592B (fr)
AP (1) AP3530A (fr)
AU (1) AU2010239085C1 (fr)
CA (1) CA2759122A1 (fr)
CO (1) CO6470806A2 (fr)
EA (1) EA201171284A1 (fr)
IL (1) IL215868A0 (fr)
MA (1) MA33299B1 (fr)
MX (1) MX344222B (fr)
NZ (2) NZ626401A (fr)
SG (2) SG175767A1 (fr)
TN (1) TN2011000536A1 (fr)
UA (1) UA111578C2 (fr)
WO (1) WO2010121326A1 (fr)
ZA (1) ZA201108648B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014MN00380A (fr) 2006-06-30 2015-06-19 Iceutica Pty Ltd
EP2421510B1 (fr) * 2009-04-24 2019-07-31 Iceutica Pty Ltd. Production de nanoparticules encapsulées à des fins commerciales
WO2010121328A1 (fr) 2009-04-24 2010-10-28 Iceutica Pty Ltd Nouvelle formulation d'indométhacine
KR101794032B1 (ko) * 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
WO2015179098A1 (fr) 2014-05-21 2015-11-26 Integenx Inc. Cartouche fluidique comprenant un mécanisme de soupape
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
NZ727270A (en) 2014-06-09 2022-07-29 Biometry Inc Low cost test strip and method to measure analyte
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
US10210410B2 (en) 2014-10-22 2019-02-19 Integenx Inc. Systems and methods for biometric data collections
KR20180104662A (ko) 2016-02-04 2018-09-21 신알엑스 파마, 엘엘씨 장애 치료를 위한 중수소화된 돔페리돈 조성물 및 방법
CA3031247A1 (fr) 2016-07-19 2018-01-25 Biometry Inc. Procedes et systemes de mesure d'analytes a l'aide de bandelettes reactives pouvant etre etalonnees par lots
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
JP2020517578A (ja) * 2017-04-21 2020-06-18 バイオ−シネクティクス インク．Ｂｉｏ−Ｓｙｎｅｃｔｉｃｓ Ｉｎｃ． 脂質を製粉工程の潤滑剤として用いる活性物質のナノ粒子の製造方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
US11779541B2 (en) 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
DE60203506T2 (de) * 2001-06-22 2006-02-16 Marie Lindner Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
CA2858733C (fr) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Composition de nanoparticules et procedes de synthese de cette derniere
IN2014MN00380A (fr) * 2006-06-30 2015-06-19 Iceutica Pty Ltd
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
NZ595973A (en) * 2009-04-24 2014-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
EP2421510B1 (fr) * 2009-04-24 2019-07-31 Iceutica Pty Ltd. Production de nanoparticules encapsulées à des fins commerciales
CN102740836A (zh) * 2009-04-24 2012-10-17 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法
CN102438600A (zh) * 2009-04-24 2012-05-02 伊休蒂卡有限公司 用于改善生物活性物质溶出度特征的方法

Also Published As

Publication number Publication date
AP3530A (en) 2016-01-13
EP2421512A4 (fr) 2013-01-23
CO6470806A2 (es) 2012-06-29
ZA201108648B (en) 2013-01-30
JP2012524722A (ja) 2012-10-18
KR20150008909A (ko) 2015-01-23
JP2015166379A (ja) 2015-09-24
CN102438592A (zh) 2012-05-02
CN102438592B (zh) 2016-09-14
SG10201401720RA (en) 2014-06-27
US20150313857A1 (en) 2015-11-05
IL215868A0 (en) 2012-01-31
AU2010239085B2 (en) 2014-07-03
AP2011005991A0 (en) 2011-12-31
NZ626401A (en) 2015-12-24
KR20160135370A (ko) 2016-11-25
AU2010239085C1 (en) 2014-10-16
TN2011000536A1 (en) 2013-05-24
US20150087709A1 (en) 2015-03-26
JP6116244B2 (ja) 2017-04-19
MX2011011220A (es) 2012-02-08
WO2010121326A1 (fr) 2010-10-28
US20160220518A1 (en) 2016-08-04
AU2010239085A1 (en) 2011-11-10
UA111578C2 (uk) 2016-05-25
CN103877030A (zh) 2014-06-25
JP6177275B2 (ja) 2017-08-09
MX344222B (es) 2016-12-07
NZ595985A (en) 2014-07-25
US20120148634A1 (en) 2012-06-14
EA201171284A1 (ru) 2012-05-30
CA2759122A1 (fr) 2010-10-28
SG175767A1 (en) 2011-12-29
US20140200276A1 (en) 2014-07-17
EP2421512A1 (fr) 2012-02-29
KR20120104489A (ko) 2012-09-21

Similar Documents

Publication Publication Date Title
MA33299B1 (fr) Nouvelle formulation de naproxène
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA33297B1 (fr) Production de nanoparticules encapsulées à des fractions volumiques élevées
MA33292B1 (fr) Production de nanoparticules encapsulees a des fins commerciales
MA35567B1 (fr) Nouvelle formulation de méloxicam
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MX360019B (es) Una formulación novedosa de metaxalona.
MA34474B1 (fr) Agonistes de gpr40
MA37610B1 (fr) Formulations de testostérone proliposomales
ATE417607T1 (de) Sphingolipide gegen krankhafte prozesse in lipid rafts
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30720B1 (fr) Analogues de 2-phenoxypyrimidinone
MA29922B1 (fr) NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet
FR2913885B1 (fr) Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
MA33512B1 (fr) Inhibiteurs de la cathepsine c
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.
MA42297B1 (fr) Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA38655A1 (fr) Nouveaux composés destinés au traitement du cancer